André J scheen
André J scheen
CHU Liège, Liège Université
Verifierad e-postadress på chuliege.be
Titel
Citeras av
Citeras av
År
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a …
JA Dormandy, B Charbonnel, DJA Eckland, E Erdmann, ...
The Lancet 366 (9493), 1279-1289, 2005
45012005
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
LF Van Gaal, AM Rissanen, AJ Scheen, O Ziegler, S Rössner, ...
The Lancet 365 (9468), 1389-1397, 2005
18772005
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular …
Authors/Task Force Members, L Rydén, PJ Grant, SD Anker, C Berne, ...
European heart journal 34 (39), 3035-3087, 2013
18142013
Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes
N Esser, S Legrand-Poels, J Piette, AJ Scheen, N Paquot
Diabetes research and clinical practice 105 (2), 141-150, 2014
11882014
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study
AJ Scheen, N Finer, P Hollander, MD Jensen, LF Van Gaal, ...
The lancet 368 (9548), 1660-1672, 2006
9222006
Clinical pharmacokinetics of metformin
AJ Scheen
Clinical pharmacokinetics 30 (5), 359-371, 1996
6371996
Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty
FH Luyckx, C Desaive, A Thiry, W Dewe, AJ Scheen, JE Gielen, ...
International journal of obesity 22 (3), 222-226, 1998
5771998
Roles of circadian rhythmicity and sleep in human glucose regulation
E Van Cauter, KS Polonsky, AJ Scheen
Endocrine reviews 18 (5), 716-738, 1997
5621997
Effect of nateglinide on the incidence of diabetes and cardiovascular events
NAVIGATOR Study Group
New England Journal of Medicine 362 (16), 1463-1476, 2010
4782010
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
AF Hernandez, JB Green, S Janmohamed, RB D'Agostino Sr, CB Granger, ...
The Lancet 392 (10157), 1519-1529, 2018
4732018
Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication
MA De Hert, R van Winkel, D Van Eyck, L Hanssens, M Wampers, ...
Schizophrenia research 83 (1), 87-93, 2006
4322006
Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss
FH Luyckx, PJ Lefebvre, AJ Scheen
Elsevier Masson, 2008
4292008
Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system
AJ Scheen
Drugs 64 (22), 2537-2565, 2004
3962004
Magnesium and glucose homeostasis
G Paolisso, A Scheen, F d'Onofrio, P Lefebvre
Diabetologia 33 (9), 511-514, 1990
3671990
Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials.
A Scheen
Diabetes and Metabolism 30 (6), 487-96, 2004
3552004
Pharmacodynamics, efficacy and safety of sodium–glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus
AJ Scheen
Drugs 75 (1), 33-59, 2015
3332015
Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective …
M De Hert, V Schreurs, K Sweers, D Van Eyck, L Hanssens, S Šinko, ...
Schizophrenia research 101 (1-3), 295-303, 2008
3232008
Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study
M De Hert, R van Winkel, D Van Eyck, L Hanssens, M Wampers, ...
Clinical Practice and Epidemiology in Mental Health 2 (1), 14, 2006
3102006
Pharmacokinetics of dipeptidylpeptidase‐4 inhibitors
AJ Scheen
Diabetes, Obesity and Metabolism 12 (8), 648-658, 2010
2982010
Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: The NESTOR* study
M Marre, JG Puig, F Kokot, M Fernandez, G Jermendy, L Opie, V Moyseev, ...
Journal of hypertension 22 (8), 1613-1622, 2004
2962004
Systemet kan inte utföra åtgärden just nu. Försök igen senare.
Artiklar 1–20